{
    "Clinical Trial ID": "NCT00086957",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Phase I: Dose Level 1 - Docetaxel 75 mg/m^2",
        "  Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 weeks.",
        "INTERVENTION 2: ",
        "  Phase I: Dose Level 2 - Docetaxel 60 mg/m^2",
        "  Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 60 mg/m^2 intravenously every 3 weeks."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed adenocarcinoma of the breast",
        "  Metastatic disease",
        "  HER-2/neu overexpression (3+ by immunohistochemistry OR 2+ by fluorescence in situ hybridization)",
        "  Measurable or evaluable disease",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  18 and over",
        "  Sex",
        "  Male or female",
        "  Menopausal status",
        "  Not specified",
        "  Performance status",
        "  ECOG 0-2",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  Absolute granulocyte count  1,500/mm^3",
        "  Platelet count  100,000/mm^3",
        "  Hepatic",
        "  AST and ALT < 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastases)",
        "  Bilirubin < 1.5 times ULN",
        "  No unstable or uncompensated hepatic disease",
        "  Renal",
        "  Creatinine < 1.6 mg/dL",
        "  No unstable or uncompensated renal disease",
        "  Cardiovascular",
        "  LVEF > 45% by echocardiogram or MUGA",
        "  No prior New York Heart Association class I-IV heart disease",
        "  No prolonged PR interval or atrioventricular block on ECG",
        "  No unstable or uncompensated cardiac disease",
        "  Pulmonary",
        "  No unstable or uncompensated respiratory disease",
        "  No clinically active interstitial lung disease",
        "  Patients who are asymptomatic and have chronic stable radiographic changes are allowed",
        "  Immunologic",
        "  No autoimmune disorders",
        "  No conditions of immunosuppression",
        "  No severe hypersensitivity to taxane or gefitinib or any of its excipients",
        "  Other",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  No other prior or concurrent malignancy within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix",
        "  No other severe or uncontrolled systemic disease",
        "  No other acute or chronic medical condition that would preclude study participation",
        "  No other significant clinical disorder or laboratory finding that would preclude study participation",
        "  No psychiatric illness that would preclude study compliance",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  Prior adjuvant trastuzumab (Herceptin\u00ae) allowed if > 6 months elapsed before disease recurrence",
        "  No prior trastuzumab for metastatic breast cancer",
        "  No prior monoclonal antibodies directed at the epidermal growth factor receptor (EGFR)",
        "  Chemotherapy",
        "  Prior adjuvant chemotherapy (or as first-line therapy for metastatic breast cancer) allowed",
        "  Prior adjuvant taxane allowed if completed > 6 months before diagnosis of metastatic breast cancer",
        "  No prior docetaxel for metastatic breast cancer",
        "  Endocrine therapy",
        "  Prior adjuvant hormonal therapy (or as first-line therapy for metastatic breast cancer) allowed",
        "  No concurrent hormonal therapy",
        "  Concurrent steroids allowed provided dose is stable",
        "  Radiotherapy",
        "  Not specified",
        "  Surgery",
        "  Fully recovered from prior oncologic or other major surgery",
        "  No concurrent surgery within 7 days of gefitinib administration",
        "  Other",
        "  Recovered from prior anticancer therapy (alopecia allowed)",
        "  More than 30 days since prior non-approved drug or investigational agent",
        "  No other prior EGFR-directed therapy (i.e., tyrosine kinase inhibitors)",
        "  No concurrent use of any of the following medications:",
        "  Phenytoin",
        "  Carbamazepine",
        "  Barbiturates",
        "  Rifampin",
        "  Hypericum perforatum (St. John's wort)",
        "  No other concurrent anticancer therapy",
        "  No concurrent cardioprotective drugs",
        "  No concurrent oral retinoids",
        "  Concurrent participation in the City of Hope indium-labeled trastuzumab imaging study allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With at Least One Dose Limiting Toxicity in Phase I",
        "  Dose Limiting Toxicity (DLT) defined as any treatment-related grade 3 or greater except for hematological toxicities which must be grade 4. Interstitial Lung Disease (ILD) related to treatment should be considered as a DLT regardless of the grade.",
        "  Time frame: 4 weeks from start of treatment, up to 2 years",
        "Results 1: ",
        "  Arm/Group Title: Phase I: Dose Level 1 - Docetaxel 75 mg/m^2",
        "  Arm/Group Description: Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 weeks.",
        "  Overall Number of Participants Analyzed: 2",
        "  Measure Type: Number",
        "  Unit of Measure: participants with DLTs  2",
        "Results 2: ",
        "  Arm/Group Title: Phase I: Dose Level 2 - Docetaxel 60 mg/m^2",
        "  Arm/Group Description: Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 60 mg/m^2 intravenously every 3 weeks.",
        "  Overall Number of Participants Analyzed: 7",
        "  Measure Type: Number",
        "  Unit of Measure: participants with DLTs  0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/2 (100.00%)",
        "  Febrile neutropenia * 2/2 (100.00%)",
        "  Haemorrhage NOS * 0/2 (0.00%)",
        "  Abdominal pain * 0/2 (0.00%)",
        "  Diarrhea * 0/2 (0.00%)",
        "  Melaena * 0/2 (0.00%)",
        "  Mucositis oral * 0/2 (0.00%)",
        "  Nausea * 0/2 (0.00%)",
        "  Vomiting * 0/2 (0.00%)",
        "  Catheter related infection * 0/2 (0.00%)",
        "  Infection NOS * 0/2 (0.00%)",
        "  Leukopenia * 1/2 (50.00%)",
        "Adverse Events 2:",
        "  Total: 7/29 (24.14%)",
        "  Febrile neutropenia * 1/29 (3.45%)",
        "  Haemorrhage NOS * 1/29 (3.45%)",
        "  Abdominal pain * 1/29 (3.45%)",
        "  Diarrhea * 2/29 (6.90%)",
        "  Melaena * 1/29 (3.45%)",
        "  Mucositis oral * 1/29 (3.45%)",
        "  Nausea * 1/29 (3.45%)",
        "  Vomiting * 1/29 (3.45%)",
        "  Catheter related infection * 1/29 (3.45%)",
        "  Infection NOS * 2/29 (6.90%)",
        "  Leukopenia * 0/29 (0.00%)"
    ]
}